----

----

| Delaware                                                      |   | 06-1123096                          |
|---------------------------------------------------------------|--------|-------------------------------------|
| (State or other jurisdiction ofincorporation or organization) |   | (I.R.S. employeridentification no.) |

----

----

| PART I     | Financial Information                                                                                     | Page No. |
|------------|-----------------------------------------------------------------------------------------------------------|----------|
|       |                                                                                                      |     |
| Item 1     | Financial Statements (Unaudited)                                                                          |     |
|       |                                                                                                      |     |
|       | Condensed Consolidated Balance Sheets as of June 30, 2010 and December 31, 2009                           | 3        |
|       |                                                                                                      |     |
|       | Condensed Consolidated Statements of Operations for the Three and Six Months Ended June 30, 2010 and 2009 | 5        |
|       |                                                                                                      |     |
|       | Condensed Consolidated Statements of Cash Flows for the Six Months Ended June 30, 2010 and 2009           | 6        |
|       |                                                                                                      |     |
|       | Notes to Condensed Consolidated Financial Statements                                                      | 7        |
|       |                                                                                                      |     |
| Item 2     | Management’s Discussion and Analysis of Financial Condition and Results of Operations               | 11       |
|       |                                                                                                      |     |
| Item 3     | Quantitative and Qualitative Disclosures about Market Risk                                                | 16       |
|       |                                                                                                      |     |
| Item 4     | Controls and Procedures                                                                                   | 17       |
|       |                                                                                                      |     |
| PART II    | Other Information                                                                                         |     |
|       |                                                                                                      |     |
| Item 1     | Legal Proceedings                                                                                         | 17       |
|       |                                                                                                      |     |
| Item 6     | Exhibits                                                                                                  | 18       |
|       |                                                                                                      |     |
| Signatures |                                                                                                      | 19       |
|       |                                                                                                      |     |

----

|                                      |   |    |       |   |         |   |
|-------------------------------------------|--------|---------|------------|--------|--------------|--------|
| Assets                                    |   | June 30 |       |   | December 31, |   |
|                                      |   | 2010    |       |   | 2009         |   |
| Current assets:                           |   |    |       |   |         |   |
| Cash and cash equivalents                 |   | $       | 3,318,003  |   |         | $      | 1,186,779 |   |
| Accounts receivable, net of allowance     |   |    | 4,962,321  |   |         |   | 4,192,730 |   |
| Recoverable income taxes                  |   |    | 93,889     |   |         |   | 871,206 |   |
| Inventories                               |   |    | 6,211,266  |   |         |   | 7,806,912 |   |
| Other current assets                      |   |    | 819,921    |   |         |   | 383,152 |   |
|                                      |   |    |       |   |         |   |   |   |
|                                      |   |    |       |   |         |   |   |   |
| Total current assets                      |   |    | 15,405,400 |   |         |   | 14,440,779 |   |
|                                      |   |    |       |   |         |   |   |   |
| Property and equipment:                   |   |    |       |   |         |   |   |   |
| Property and equipment                    |   |    | 5,798,622  |   |         |   | 5,718,078 |   |
| Equipment at customers                    |   |    | 1,347,230  |   |         |   | 1,219,418 |   |
|                                      |   |    |       |   |         |   |   |   |
|                                      |   |    | 7,145,852  |   |         |   | 6,937,496 |   |
| Accumulated depreciation and amortization |   |    | (5,389,257 | )      |         |   | (4,976,819 | ) |
|                                      |   |    |       |   |         |   |   |   |
|                                      |   |    | 1,756,595  |   |         |   | 1,960,677 |   |
|                                      |   |    |       |   |         |   |   |   |
| Intangible and other assets, net          |   |    | 734,621    |   |         |   | 625,761 |   |
|                                      |   |    |       |   |         |   |   |   |
| Goodwill                                  |   |    | 1,223,236  |   |         |   | 1,223,236 |   |
|                                      |   |    |       |   |         |   |   |   |
| Total assets                              |   | $       | 19,119,852 |   |         | $      | 18,250,453 |   |

----

|                                                                                                                                                                                                   |   |     |       |   |         |   |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|----------|------------|--------|--------------|--------|
|                                                                                                                                                                                                   |   | June 30, |       |   | December 31, |   |
| Liabilities and Stockholders’ Equity                                                                                                                                                             |   | 2010     |       |   | 2009         |   |
|                                                                                                                                                                                                   |   |     |       |   |         |   |
| Current liabilities:                                                                                                                                                                                   |   |     |       |   |         |   |
| Current portion of long-term debt                                                                                                                                                                      |   | $        | 672,526    |   |         | $      | 652,482 |   |
| Line-of-credit                                                                                                                                                                                         |   |     | 1,475,000  |   |         |   | 2,669,657 |   |
| Notes payable                                                                                                                                                                                          |   |     | 133,815    |   |         |   | 50,678 |   |
| Accounts payable                                                                                                                                                                                       |   |     | 2,169,652  |   |         |   | 1,848,185 |   |
| Accrued expenses                                                                                                                                                                                       |   |     | 1,213,410  |   |         |   | 1,313,164 |   |
|                                                                                                                                                                                                   |   |     |       |   |         |   |   |   |
|                                                                                                                                                                                                   |   |     |       |   |         |   |   |   |
| Total current liabilities                                                                                                                                                                              |   |     | 5,664,403  |   |         |   | 6,534,166 |   |
|                                                                                                                                                                                                   |   |     |       |   |         |   |   |   |
| Long-term debt, less current portion                                                                                                                                                                   |   |     | 714,870    |   |         |   | 1,056,273 |   |
| Deferred gain on sale and leaseback of property                                                                                                                                                        |   |     | 966,745    |   |         |   | 1,034,064 |   |
| Income taxes payable                                                                                                                                                                                   |   |     | 190,159    |   |         |   | 277,280 |   |
|                                                                                                                                                                                                   |   |     |       |   |         |   |   |   |
|                                                                                                                                                                                                   |   |     |       |   |         |   |   |   |
| Total liabilities                                                                                                                                                                                      |   |     | 7,536,177  |   |         |   | 8,901,783 |   |
|                                                                                                                                                                                                   |   |     |       |   |         |   |   |   |
| Commitments and contingencies                                                                                                                                                                          |   |     |       |   |         |   |   |   |
|                                                                                                                                                                                                   |   |     |       |   |         |   |   |   |
| Stockholders’ equity:                                                                                                                                                                            |   |     |       |   |         |   |   |   |
| Series A cumulative convertible preferred stock, $.001 par value per share, 1,000,000 shares authorized, no shares issued or outstanding                                                               |   |     | —    |   |         |   | — |   |
| Common stock, $.004 par value per share, 40,000,000 shares authorized, 13,018,495 and 11,610,075 shares issued at June 30, 2010 and December 31, 2009, respectively, including shares held in treasury |   |     | 52,074     |   |         |   | 46,440 |   |
| Common stock held in treasury, at cost - 86,000 shares                                                                                                                                                 |   |     | (101,480   | )      |         |   | (101,480 | ) |
| Additional paid-in capital                                                                                                                                                                             |   |     | 9,675,237  |   |         |   | 7,661,060 |   |
| Retained earnings                                                                                                                                                                                      |   |     | 1,957,844  |   |         |   | 1,742,650 |   |
|                                                                                                                                                                                                   |   |     |       |   |         |   |   |   |
|                                                                                                                                                                                                   |   |     |       |   |         |   |   |   |
| Total stockholders’ equity                                                                                                                                                                       |   |     | 11,583,675 |   |         |   | 9,348,670 |   |
|                                                                                                                                                                                                   |   |     |       |   |         |   |   |   |
| Total liabilities and stockholders’ equity                                                                                                                                                       |   | $        | 19,119,852 |   |         | $      | 18,250,453 |   |
|                                                                                                                                                                                                   |   |     |       |   |         |   |   |   |

----

|                                |   | Three Months Ended |       |   | Six Months Ended |   |
|-------------------------------------|--------|--------------------|------------|--------|------------------|--------|
|                                |   | June 30,           |       |   | June 30,         |   |
|                                |   | 2010               |       |   | 2009             |   |   | 2010 |   |   | 2009 |   |
|                                |   |               |       |   |             |   |   |   |   |   |   |   |
| Net sales                           |   | $                  | 8,224,442  |   |             | $      | 8,568,115 |   |   | $ | 16,719,474 |   |   | $ | 16,973,939 |   |
|                                |   |               |       |   |             |   |   |   |   |   |   |   |   |   |   |   |
| Cost of sales                       |   |               | 5,066,671  |   |             |   | 5,975,792 |   |   |   | 10,605,723 |   |   |   | 11,916,487 |   |
|                                |   |               |       |   |             |   |   |   |   |   |   |   |   |   |   |   |
| Gross profit                        |   |               | 3,157,771  |   |             |   | 2,592,323 |   |   |   | 6,113,751 |   |   |   | 5,057,452 |   |
|                                |   |               |       |   |             |   |   |   |   |   |   |   |   |   |   |   |
| Operating expenses:                 |   |               |       |   |             |   |   |   |   |   |   |   |   |   |   |   |
| Research and development            |   |               | 468,163    |   |             |   | 577,843 |   |   |   | 932,144 |   |   |   | 1,204,038 |   |
| Selling, general and administrative |   |               | 2,676,297  |   |             |   | 3,178,141 |   |   |   | 4,874,627 |   |   |   | 6,389,269 |   |
|                                |   |               | 3,144,460  |   |             |   | 3,755,984 |   |   |   | 5,806,771 |   |   |   | 7,593,307 |   |
|                                |   |               |       |   |             |   |   |   |   |   |   |   |   |   |   |   |
| Operating income (loss)             |   |               | 13,311     |   |             |   | (1,163,661 | ) |   |   | 306,980 |   |   |   | (2,535,855 | ) |
|                                |   |               |       |   |             |   |   |   |   |   |   |   |   |   |   |   |
| Interest expense, net               |   |               | 44,846     |   |             |   | 62,875 |   |   |   | 93,916 |   |   |   | 112,519 |   |
|                                |   |               |       |   |             |   |   |   |   |   |   |   |   |   |   |   |
| (Loss) income before income taxes   |   |               | (31,535    | )      |             |   | (1,226,536 | ) |   |   | 213,064 |   |   |   | (2,648,374 | ) |
|                                |   |               |       |   |             |   |   |   |   |   |   |   |   |   |   |   |
| Income tax benefit                  |   |               | (39,207    | )      |             |   | (392,878 | ) |   |   | (2,130 | ) |   |   | (911,848 | ) |
|                                |   |               |       |   |             |   |   |   |   |   |   |   |   |   |   |   |
| Net income (loss)                   |   | $                  | 7,672      |   |             | $      | (833,658 | ) |   | $ | 215,194 |   |   | $ | (1,736,526 | ) |
|                                |   |               |       |   |             |   |   |   |   |   |   |   |   |   |   |   |
| Income (loss) per common share:     |   |               |       |   |             |   |   |   |   |   |   |   |   |   |   |   |
|                                |   |               |       |   |             |   |   |   |   |   |   |   |   |   |   |   |
| Basic                               |   | $                  | 0.00       |   |             | $      | (0.07 | ) |   | $ | 0.02 |   |   | $ | (0.15 | ) |
|                                |   |               |       |   |             |   |   |   |   |   |   |   |   |   |   |   |
| Diluted                             |   | $                  | 0.00       |   |             | $      | (0.07 | ) |   | $ | 0.02 |   |   | $ | (0.15 | ) |
|                                |   |               |       |   |             |   |   |   |   |   |   |   |   |   |   |   |
| Weighted average number of          |   |               |       |   |             |   |   |   |   |   |   |   |   |   |   |   |
| common shares outstanding:          |   |               |       |   |             |   |   |   |   |   |   |   |   |   |   |   |
| Basic                               |   |               | 11,617,719 |   |             |   | 11,224,829 |   |   |   | 11,480,541 |   |   |   | 11,218,419 |   |
|                                |   |               |       |   |             |   |   |   |   |   |   |   |   |   |   |   |
| Diluted                             |   |               | 12,372,575 |   |             |   | 11,224,829 |   |   |   | 12,311,303 |   |   |   | 11,218,419 |   |
|                                |   |               |       |   |             |   |   |   |   |   |   |   |   |   |   |   |

----

|                                                                                              |   | Six Months Ended |       |
|---------------------------------------------------------------------------------------------------|--------|------------------|------------|
|                                                                                              |   | June 30,         |       |
|                                                                                              |   | 2010             |       |   | 2009 |   |
| OPERATING ACTIVITIES:                                                                             |   |             |       |   |   |   |
| Net income (loss)                                                                                 |   | $                | 215,194    |   |   | $ | (1,736,526 | ) |
| Adjustments to reconcile net income (loss) to net cash provided (used) by operating activities:   |   |             |       |   |   |   |   |   |
| Depreciation and amortization                                                                     |   |             | 496,862    |   |   |   | 628,807 |   |
| Deferred income taxes                                                                             |   |             | —    |   |   |   | (809,588 | ) |
| Non-cash stock compensation                                                                       |   |             | 83,033     |   |   |   | 166,417 |   |
| Amortization of deferred gain on sale and leaseback of property                                   |   |             | (67,319    | ) |   |   | (67,319 | ) |
| Changes in operating assets and liabilities:                                                      |   |             |       |   |   |   |   |   |
| Accounts receivable                                                                               |   |             | (769,591   | ) |   |   | (686,677 | ) |
| Other receivable                                                                                  |   |             | —    |   |   |   | 715,769 |   |
| Inventories                                                                                       |   |             | 1,595,646  |   |   |   | 502,114 |   |
| Other current assets                                                                              |   |             | (436,769   | ) |   |   | (82,092 | ) |
| Recoverable income taxes, net                                                                     |   |             | 777,317    |   |   |   | (114,577 | ) |
| Income taxes payable                                                                              |   |             | (87,121    | ) |   |   | 5,500 |   |
|           Accounts payable and accrued expenses |   |             | 221,714    |   |   |   | 383,372 |   |
| Net cash provided (used) by operating activities                                                  |   |             | 2,028,966  |   |   |   | (1,094,800 | ) |
|                                                                                              |   |             |       |   |   |   |   |   |
| INVESTING ACTIVITIES:                                                                             |   |             |       |   |   |   |   |   |
| Expenditures for property and equipment                                                           |   |             | (208,357   | ) |   |   | (179,756 | ) |
| Purchase of intangible assets                                                                     |   |             | (70,065    | ) |   |   | (59,544 | ) |
| Net cash used by investing activities                                                             |   |             | (278,422   | ) |   |   | (239,300 | ) |
|                                                                                              |   |             |       |   |   |   |   |   |
| FINANCING ACTIVITIES:                                                                             |   |             |       |   |   |   |   |   |
| Repayments of long-term debt                                                                      |   |             | (321,359   | ) |   |   | (302,774 | ) |
| Borrowings under note payable                                                                     |   |             | 244,875    |   |   |   | 228,052 |   |
| Repayments of note payable                                                                        |   |             | (161,738   | ) |   |   | (25,339 | ) |
| Deferred financing costs                                                                          |   |             | (123,219   | ) |   |   | — |   |
| (Repayments) advances from line-of-credit, net                                                    |   |             | (1,194,657 | ) |   |   | 1,129,269 |   |
| Proceeds from issuance of common stock                                                            |   |             | 1,936,778  |   |   |   | 37,233 |   |
| Net cash provided by financing activities                                                         |   |             | 380,680    |   |   |   | 1,066,441 |   |
|                                                                                              |   |             |       |   |   |   |   |   |
| Change in cash and cash equivalents                                                               |   |             | 2,131,224  |   |   |   | (267,659 | ) |
|                                                                                              |   |             |       |   |   |   |   |   |
| Cash and cash equivalents, beginning of period                                                    |   |             | 1,186,779  |   |   |   | 1,082,619 |   |
|                                                                                              |   |             |       |   |   |   |   |   |
| Cash and cash equivalents, end of period                                                          |   | $                | 3,318,003  |   |   | $ | 814,960 |   |
|                                                                                              |   |             |       |   |   |   |   |   |
| Supplemental Disclosures of Cash Flow Information:                                                |   |             |       |   |   |   |   |   |
|                                                                                              |   |             |       |   |   |   |   |   |
| Cash paid during the period for interest                                                          |   | $                | 99,136     |   |   | $ | 109,616 |   |
| Cash paid (refunded) during the period for income taxes, net                                      |   | $                | (750,777   | ) |   | $ | 6,818 |   |
|                                                                                              |   |             |       |   |   |   |   |   |
| See accompanying notes.                                                                           |   |             |       |   |   |   |   |   |

----

| (1)   | The Company |
|-----------------|-------------|

| (2)  | Basis of Presentation |
|-----------|-----------------------|

| (3)  | Inventories; Property and Equipment; Intangible and Other Assets and Goodwill |
|-----------|-------------------------------------------------------------------------------|

|            |   | June 30, |      |   | December 31, |   |
|-----------------|--------|----------|-----------|--------|--------------|--------|
|            |   | 2010     |      |   | 2009         |   |
|            |   |     |      |   |         |   |
| Raw materials   |   | $        | 5,010,576 |   |         | $      | 6,185,097 |   |
| Work in process |   |     | 37,587    |   |         |   | 39,544 |   |
| Finished goods  |   |     | 1,163,103 |   |         |   | 1,582,271 |   |
|            |   | $        | 6,211,266 |   |         | $      | 7,806,912 |   |

----

|                     |   | June 30, |      |   | December 31, |   |
|--------------------------|--------|----------|-----------|--------|--------------|--------|
|                     |   | 2010     |      |   | 2009         |   |
|                     |   |     |      |   |         |   |
| Patents and other assets |   | $        | 623,864   |   |         | $      | 606,271 |   |
| Patents pending          |   |     | 250,253   |   |         |   | 240,981 |   |
| Purchase technology      |   |     | 33,893    |   |         |   | 33,893 |   |
| Capitalized software     |   |     | 179,946   |   |         |   | 179,946 |   |
| Deferred finance charges |   |     | 170,204   |   |         |   |  46,986 |   |
|                     |   |     | 1,258,160 |   |         |   | 1,108,077 |   |
| Accumulated amortization |   |     | (523,539  | )      |         |   |  (482,316 | ) |
|                     |   | $        | 734,621   |   |         | $      | 625,761 |   |

| 2011   |   | $      | 77,000  |   |
|--------|--------|--------|---------|--------|
| 2012   |   |   | 37,000  |   |
| 2013   |   |   | 24,000  |   |
| 2014   |   |   | 20,000  |   |
| 2015   |   |   | 19,000  |   |
|   |   | $      | 177,000 |   |

| (4)  | Principal Products and Services |
|-----------|---------------------------------|

|   | ·   | Critical care monitoring products – includes sales of the FORE-SIGHT® cerebral monitors, sensors and accessories. |
|--------|--------------------|------------------------------------------------------------------------------------------------------------------------------|

|   | ·   | Bedside monitoring products – includes sales of the Company’s vital signs and bedside monitors and accessories incorporating various combinations of measurement parameters for both human and veterinary |
|--------|--------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

|   | ·   | use. Parameters found in these monitors include the Company’s proprietary MAXNIBP® non-invasive blood pressure, pulse oximetry, electro-cardiography, temperature, and capnography. |
|--------|--------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | ·   | Blood pressure measurement technology – includes sales to OEM manufacturers of the Company’s proprietary MAXNIBP® non-invasive blood pressure technology, sold as a discrete module to be included in the OEM customers own multi-parameter monitors, and associate blood pressure cuffs and accessories for the OEM market and related license fees. |
|--------|--------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | ·   | Supplies and service – includes sales of blood pressure cuffs and rapid infusor cuffs, neonatal intensive care supplies including electrodes and skin temperature probes, and service repair. |
|--------|--------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (5) | Income (Loss) per Common Share |
|-----|--------------------------------|

|                                                                                                                         |   | Three Months Ended |       |   | Six Months Ended |   |
|------------------------------------------------------------------------------------------------------------------------------|--------|--------------------|------------|--------|------------------|--------|
|                                                                                                                         |   | June 30,           |       |   | June 30,         |   |
|                                                                                                                         |   | 2010               |       |   | 2009             |   |   | 2010 |   |   | 2009 |   |
|                                                                                                                         |   |               |       |   |             |   |   |   |   |   |   |   |
| Weighted average shares outstanding, net of restricted shares – used to compute basic income (loss) per share     |   |               | 11,617,719 |   |             |   | 11,224,829 |   |   |   | 11,480,541 |   |   |   | 11,218,419 |   |
|                                                                                                                         |   |               |       |   |             |   |   |   |   |   |   |   |   |   |   |   |
| Dilutive effect of restricted shares, and outstanding warrants and options                                              |   |               | 754,856    |   |             |   | — |   |   |   | 830,762 |   |   |   | — |   |
|                                                                                                                         |   |               |       |   |             |   |   |   |   |   |   |   |   |   |   |   |
| Weighted average shares of dilutive securities outstanding – used to compute diluted income (loss) per share |   |               | 12,372,575 |   |             |   | 11,224,829 |   |   |   | 12,311,303 |   |   |   | 11,218,419 |   |

| (6)  | Stock-Based Compensation |
|-----------|--------------------------|

----

|                             |   |   |    |   |             |   |    | Aggregate |   |   | Weighted-Average   |   |
|----------------------------------|--------|--------|---------|--------|------------------|--------|---------|-----------|--------|--------|--------------------|--------|
|                             |   | Option |    |   | Weighted-Average |   |    | Intrinsic |   |   | Contractual Life   |   |
|                             |   | Shares |    |   | Exercise Price   |   |    | Value (1) |   |   | Remaining in Years |   |
| Outstanding at December 31, 2009 |   |   | 488,175 |   |             | $      | 2.19    |      |   | $      | 233,619            |   |   |   | 4.8 |   |
| Granted                          |   |   | 70,000  |   |             |   | 2.04    |      |   |   |               |   |   |   |   |   |
| Cancelled                        |   |   | (40,000 | )      |             |   | 3.49    |      |   |   |               |   |   |   |   |   |
| Exercised                        |   |   | — |   |             |   | — |      |   |   |               |   |   |   |   |   |
| Outstanding at June 30, 2010     |   |   | 518,175 |   |             | $      | 2.07    |      |   | $      | 152,376            |   |   |   | 4.7 |   |
| Exercisable at June 30, 2010     |   |   | 441,508 |   |             | $      | 2.07    |      |   | $      | 152,376            |   |   |   | 3.8 |   |

| (7) | Financing Arrangements |
|-----|------------------------|

----

| (8) | Income Taxes |
|-----|--------------|

| (9) | Litigation |
|-----|------------|

----

|                                  |   | Three Months Ended |        |   | Three Months Ended |   |   | Increase/  |   |
|---------------------------------------|--------|--------------------|-------------|--------|--------------------|--------|--------|------------|--------|
| ($000’s)                        |   | June 30, 2010      |        |   | June 30, 2009      |   |   | (Decrease) |   |
| Bedside Monitoring Products           |   | $                  | 2,279       |   |               | $      | 3,068  |       |   | $ | (789 | ) |
| Critical Care Monitoring Products     |   |               | 1,382       |   |               |   | 982    |       |   |   | 400 |   |
| Blood Pressure Measurement Technology |   |               | 1,607       |   |               |   | 1,476  |       |   |   | 131 |   |
| Supplies and Service                  |   |               |  2,956 |   |               |   | 3,042  |       |   |   |  (86 | ) |
|                                  |   | $                  | 8,224       |   |               | $      | 8,568  |       |   | $ | (344 | ) |
|                                  |   |               |        |   |               |   |   |       |   |   |   |   |
| Domestic Sales                        |   | $                  | 5,802       |   |               | $      | 5,589  |       |   | $ | 213 |   |
| International Sales                   |   |               |  2,422 |   |               |   | 2,979  |       |   |   |  (557 | ) |
|                                  |   | $                  | 8,224       |   |               | $      | 8,568  |       |   | $ | ( 344 | ) |

----

|                                  |   | Six Months Ended |        |   | Six Months Ended |   |   | Increase/  |   |
|---------------------------------------|--------|------------------|-------------|--------|------------------|--------|--------|------------|--------|
| ($000’s)                        |   | June 30, 2010    |        |   | June 30, 2009    |   |   | (Decrease) |   |
| Bedside Monitoring Products           |   | $                | 3,927       |   |             | $      | 5,644  |       |   | $ | (1,717 | ) |
| Critical Care Monitoring Products     |   |             | 2,757       |   |             |   | 1,867  |       |   |   | 890 |   |
| Blood Pressure Measurement Technology |   |             | 3,629       |   |             |   | 2,959  |       |   |   | 670 |   |
| Supplies and Service                  |   |             |  6,406 |   |             |   | 6,504  |       |   |   |  (98 | ) |
|                                  |   | $                | 16,719      |   |             | $      | 16,974 |       |   | $ | (255 | ) |
|                                  |   |             |        |   |             |   |   |       |   |   |   |   |
| Domestic Sales                        |   | $                | 11,423      |   |             | $      | 11,733 |       |   | $ | (310 | ) |
| International Sales                   |   |             |  5,296 |   |             |   | 5,241  |       |   |   |  55 |   |
|                                  |   | $                | 16,719      |   |             | $      | 16,974 |       |   | $ | (255 | ) |

----

----

----

----

----

|   | 31.1   | Certification pursuant to Rule 13a-14(a) of Andrew E. Kersey, President and Chief Executive Officer |
|--------|------------------|-----------------------------------------------------------------------------------------------------|

|   | 31.2   | Certification pursuant to Rule 13a-14(a) of Jeffery A. Baird, Chief Financial Officer |
|--------|------------------|---------------------------------------------------------------------------------------|

|   | 32.1 | Certification pursuant to 18 U.S.C. 1350 of Periodic Financial Report of Andrew E. Kersey, President and Chief Executive Officer and Jeffery A. Baird, Chief Financial Officer |
|--------|------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| /s/ Andrew E. Kersey                                                                By:  Andrew E. Kersey       President and Chief Executive Officer |   | Date:  August 4, 2010 |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|---------------------------------|
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |   |                            |
| /s/ Jeffery A. Baird                                                                By:  Jeffery A. Baird       Chief Financial Officer               |   | Date:  August 4, 2010 |

----